Trial · NCT01591785
Treatment of Staphylococcus Aureus Colonization in Hand Eczema
NCT01591785, Not applicable, Completed, Gary Goldenberg; results first posted 2020-12-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment of Staphylococcus Aureus Colonization in Hand Eczema. Trials, record NCT01591785. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01591785
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Staphylococcus Aureus Colonization in Hand Eczema
- NCT number
- NCT01591785
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 60 participants, actual
- Lead sponsor
- Gary Goldenberg
- Conditions
- Hand Eczema, Foot Eczema
- Interventions
- Retapamulin 1% ointment, Placebo
- First posted
- 2012-05-04
- Last updated
- 2020-12-03
- Results first posted
- 2020-12-03
- Limitations and caveats
The study size was small. Study was only four weeks in duration, which is a snap-shot of a chronic life-long disease. Study was a single-center study which might not be a representative of the general population.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With PGA of 0 or 1 | Day 15 | Physician's Global Assessment PGA 0 = Clear (no inflammatory signs of atopic dermatitis) 1 = Almost clear (just perceptible erythema and papulation/infiltration) |
| Primary | Number of Participants With PGA of 0 or 1 | Day 28 | Physician's Global Assessment PGA 0 = Clear (no inflammatory signs of atopic dermatitis) 1 = Almost clear (just perceptible erythema and papulation/infiltration) |
| Secondary | Staph Aureus Culture Results | Day 15 | The percentage of subjects who had both negative S. aureus skin and nares cultures with a PGA of clear/almost clear at day 15 compared to baseline |
| Secondary | Staph Aureus Culture Results | Day 28 | The percentage of subjects who had both negative S. aureus skin and nares cultures with a PGA of clear/almost clear at day 28 compared to baseline |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With PGA of 0 or 1 | Day 15 | participants | NUMBER | |
| PRIMARY | Number of Participants With PGA of 0 or 1 | Day 28 | participants | NUMBER | |
| SECONDARY | Staph Aureus Culture Results | Day 15 | percentage of participants | NUMBER | |
| SECONDARY | Staph Aureus Culture Results | Day 28 | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With PGA of 0 or 1 | Retapamulin 1% Ointment | 22 | participants | ||
| Number of Participants With PGA of 0 or 1 | Placebo Ointment | 14 | participants | ||
| Number of Participants With PGA of 0 or 1 | Retapamulin 1% Ointment | 15 | participants | ||
| Number of Participants With PGA of 0 or 1 | Placebo Ointment | 11 | participants | ||
| Staph Aureus Culture Results | Retapamulin 1% Ointment | 61 | percentage of participants | ||
| Staph Aureus Culture Results | Placebo Ointment | 30 | percentage of participants | ||
| Staph Aureus Culture Results | Retapamulin 1% Ointment | 28 | percentage of participants | ||
| Staph Aureus Culture Results | Placebo Ointment | 13 | percentage of participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Retapamulin 1% Ointment | 30 | |
| Overall Study | STARTED | Placebo Ointment | 30 | |
| Overall Study | COMPLETED | Retapamulin 1% Ointment | 26 | |
| Overall Study | COMPLETED | Placebo Ointment | 28 | |
| Overall Study | NOT COMPLETED | Retapamulin 1% Ointment | 4 | |
| Overall Study | NOT COMPLETED | Placebo Ointment | 2 |
Source ClinicalTrials.gov
Adverse events10
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Urinary Tract Infection | Renal and urinary disorders | Retapamulin 1% Ointment | 1 | 30 | |
| other | Urinary Tract Infection | Renal and urinary disorders | Placebo Ointment | 0 | 30 | |
| other | Upper respiratory infection | Respiratory, thoracic and mediastinal disorders | Retapamulin 1% Ointment | 2 | 30 | |
| other | Upper respiratory infection | Respiratory, thoracic and mediastinal disorders | Placebo Ointment | 1 | 30 | |
| other | Eczema flare | Skin and subcutaneous tissue disorders | Retapamulin 1% Ointment | 1 | 30 | |
| other | Eczema flare | Skin and subcutaneous tissue disorders | Placebo Ointment | 1 | 30 | |
| other | Dryness | Skin and subcutaneous tissue disorders | Retapamulin 1% Ointment | 0 | 30 | |
| other | Dryness | Skin and subcutaneous tissue disorders | Placebo Ointment | 1 | 30 | |
| other | Pruritus | Skin and subcutaneous tissue disorders | Retapamulin 1% Ointment | 1 | 30 | |
| other | Pruritus | Skin and subcutaneous tissue disorders | Placebo Ointment | 0 | 30 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Retapamulin 1% Ointment | 0 | 30 |
| Total, all-cause mortality | Placebo Ointment | 0 | 30 |
| Total, other adverse events | Retapamulin 1% Ointment | 5 | 30 |
| Total, other adverse events | Placebo Ointment | 3 | 30 |
| Total, serious adverse events | Retapamulin 1% Ointment | 0 | 30 |
| Total, serious adverse events | Placebo Ointment | 0 | 30 |
Source ClinicalTrials.gov
Papers11
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Retapamulin 1% Ointment vs Placebo Ointment: Number of Participants With PGA of 0 or 1 | Trial comparisons |
| Retapamulin 1% Ointment vs Placebo Ointment: deaths from any cause | Trial comparisons |
| Retapamulin 1% Ointment vs Placebo Ointment: Number of Participants With PGA of 0 or 1 | Trial comparisons |
| Retapamulin 1% Ointment vs Placebo Ointment: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01591785
GET https://conductscience.org/api/trials/v1/NCT01591785/registered